TEMPEST THERAPEUTICS INC (TPST) Stock Price, Quote, News and Overview
NASDAQ:TPST - Nasdaq - US87978U1088 - Common Stock - Currency: USD
TPST Quote, Performance and Key Statistics
TEMPEST THERAPEUTICS INC
NASDAQ:TPST (2/7/2025, 8:00:16 PM)
Premarket: 0.8802 +0 (+0.43%)0.8764
-0.03 (-3.6%)
The current stock price of TPST is 0.8764 USD. In the past month the price decreased by -11.08%. In the past year, price decreased by -79.03%.
TPST Latest News and Analysis
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing...
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
BRISBANE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing...
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing...
TPST Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.83 | 336.82B | ||
| AMGN | AMGEN INC | 14.81 | 157.79B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 920.24 | 120.86B | ||
| GILD | GILEAD SCIENCES INC | 21.68 | 119.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.56 | 78.02B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.62B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.20B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.82B | ||
| NTRA | NATERA INC | N/A | 22.82B | ||
| BIIB | BIOGEN INC | 8.66 | 20.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.27 | 15.52B |
Related stock screener links
About TPST
Company Profile
Tempest Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development and discovery of small molecule drugs for the treatment of cancer. The company is headquartered in Brisbane California, California and currently employs 17 full-time employees. The company went IPO on 2012-10-04. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.
Company Info
TEMPEST THERAPEUTICS INC
2000 Sierra Point Parkway, Suite 400
Brisbane California CALIFORNIA US
CEO: Louis Arcudi
Employees: 17
Company Website: https://www.tempesttx.com/
Investor Relations: https://ir.tempesttx.com/
Phone: 14157988589
TPST FAQ
What is the stock price of TPST?
The current stock price of TPST is 0.8764 USD.
What is the symbol for TEMPEST THERAPEUTICS INC stock?
The exchange symbol of TEMPEST THERAPEUTICS INC is TPST and it is listed on the Nasdaq exchange.
On which exchange is TPST stock listed?
TPST stock is listed on the Nasdaq exchange.
Is TPST a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for TPST, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of TPST.
Does TPST stock pay dividends?
TPST does not pay a dividend.
What is the Price/Earnings (PE) ratio of TPST?
TPST does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.57).
What is the Short Interest ratio of TPST stock?
The outstanding short interest for TPST is 7.18% of its float.
TPST Technical Analysis
TPST Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TPST. While TPST seems to be doing ok healthwise, there are quite some concerns on its profitability.
TPST Financial Highlights
Over the last trailing twelve months TPST reported a non-GAAP Earnings per Share(EPS) of -1.57. The EPS decreased by 28.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -104.97% | ||
| ROE | -310.01% | ||
| Debt/Equity | 0 |
TPST Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to TPST. The Buy consensus is the average rating of analysts ratings from 11 analysts.